#lfcr

1 week ago

Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered with the ClearPen ™ , its Proprietary Intradermal Self-Injection Device Lifecore to Manufacture Drug Batches in Preparation for Planned Clinical Trials CHASKA, Minn. and BOSTON, Mass., March 04, 2026

#LFCR Lifecore Biomedical Signs New Agreement with Indomo to Support Innovative Drug/Device Combination Acne Treatment

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Lifecore Biomedical to be Added to Nasdaq Biotech Index Lifecore Biomedical (NASDAQ: LFCR) announced it will be added to the Nasdaq Biotechnology Index (NASDAQ: NBI) as part of Nasdaq's annual index reconstitution. The inclusion is expected to be effective prior to market open on Monday, December 22, 2025.The Nasdaq Biotechnology Index tracks Nasdaq-listed securities classified as biotechnology or pharmaceutical under the Industry Classification Benchmark and is calculated using a modified capitalization-weighted methodology. Constituents are selected once annually in December and must meet eligibility requirements including minimum market capitalization, average daily trading volume, and public company seasoning.

#NBI #LFCR Lifecore Biomedical to be Added to Nasdaq Biotech Index

www.stocktitan.net/news/NBI/lifecore-biomed...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer Lifecore

#LFCR Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

#LFCR Lifecore Biomedical Reports Financial Results for the Three Months Ended September 30, 2025, and Provides Corporate Update

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company Lifecore Biomedical (NASDAQ: LFCR) announced on October 29, 2025 that it signed an agreement to execute a commercial site transfer and become the commercial supplier of choice for a leading injectable pharmaceutical product after regulatory requirements are satisfied. This is the second agreement with the same multinational customer in recent months. Lifecore also signed a separate pre-clinical formulation development agreement with an early-stage biotech, expanding its early-stage pipeline.The deals are positioned to increase capacity utilization, broaden the commercial customer base, and leverage Lifecore’s fill-finish and regulatory track record as a U.S.-based CDMO for sterile injectables.

#LFCR Lifecore Biomedical Selected as New Commercial Manufacturing Partner by Leading Global Pharmaceutical Company

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market Lifecore Biomedical (NASDAQ: LFCR) and PolyPeptide announced a collaboration on October 28, 2025 to deliver an integrated end-to-end peptide manufacturing solution for the U.S. market.The agreement pairs PolyPeptide’s peptide drug substance (DS) development and manufacturing capabilities with Lifecore’s formulation, fill/finish, and packaging expertise to enable a seamless DS-to-drug product (DP) transition, with the stated goals of accelerating development timelines, lowering development costs and risks, and providing a fully U.S.-based supply chain with aligned regulatory oversight.

#LFCR Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market

www.stocktitan.net/news/LFCR/lifecore-and-p...

0 0 0 0

Option Mike

@optionmike.bsky.social

6 months ago

Good Morning!

Futures up

#LFCR int Sector Weight @ Keybanc
#ATR int Overweight @ Keybanc pt $220
#STZ pt cut $152 from $180 @ Cowen
#ASAN Overweight @ Piper pt $19
#HUBS int Overweight @ Piper pt $675
#FIG int Overweight @Piper pt $85
#APP pt raised $615 from $560 @ Jefferies
#AVGO pt raised $342

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Lifecore Biomedical FY2025 Earnings: $128.9M Revenue, Expands Beyond Ophthalmics with 9 New Programs Lifecore meets FY2025 guidance, targets 12%+ revenue CAGR. New GLP-1 therapeutics partnership and operational efficiency gains signal growth. See full results.

#LFCR Lifecore Biomedical Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

Leading Indicators, Wednesday July 30, 2025 – Crystal Equity Research

Small-cap stocks in new downtrend with AROON Oscillator, Wed Jul 30th - #RPD #QSI #PHLT #OM #NWBI #MBIN #LFCR #KARO #IBCP #HAFC #SAGE #GAIN #FCBC #EVGN #DIBS #CERS #BEAT #AARD #VFS #TDOC #SCL #TBRG - More: crystalequityresearch.com/leading-indi... - #smallcap

1 0 0 0

StockTitan

@stocktitan.net

9 months ago

Lifecore Biomedical Lands Multi-Million Dollar, 10-Year Manufacturing Contract for Novel Eye Treatment New multi-million dollar agreement expands Lifecore's commercial manufacturing portfolio in ophthalmics. See revenue growth potential and PPQ batch details.

#LFCR Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Customer

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Lifecore Biomedical Fast-Tracks $10M Equipment Payment as New Filler Promises $300M Revenue Potential Early payment strengthens balance sheet while new high-speed filler expands production capacity. See how Lifecore's strategic moves position it for substantial growth. Get details.

#LFCR Lifecore Biomedical Receives Accelerated Payment of Remaining $10 Million in Proceeds from Prior Equipment Sale

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Lifecore Biomedical Taps 30-Year Pharma Veteran as CCO to Accelerate CDMO Market Expansion Industry veteran Mark DaFonseca brings 30 years of pharma expertise to lead Lifecore's commercial transformation. Discover the three-pronged growth strategy. See details.

#LFCR Lifecore Biomedical Names Mark DaFonseca Chief Commercial Officer

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

🅱🅸🅶🅾🆁🆁🅴.🅾🆁🅶

@bigorre-org.mastodon.social.ap.brid.gy

10 months ago

Rodez-Marcillac airport (France) aviation weather and informations LFCR RDZ Aviation weather with TAF and METAR, Maps, hotels and aeronautical information for Rodez-Marcillac airport (France)

Aviation weather for Rodez-Marcillac airport (France) is “LFCR 011500Z AUTO 13017KT CAVOK 22/05 Q1018 TEMPO 14015G25KT” : See what it means on https://www.bigorre.org/aero/meteo/lfcr/en #rodez #france #rodezmarcillacairport #lfcr #rdz #metar #aviation #aviationweather #avgeek vl

0 0 0 0

InsiderFinance

@insiderfinance.com

11 months ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#TEM, #RXRX, #RKT, #LFCR, #DB

#OptionFlow #OptionsTrading #Trading

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update Lifecore Biomedical (NASDAQ: LFCR) reported Q3 fiscal 2025 financial results with revenues of $35.2 million, down 2% from $35.7 million in the prior year period. The company recorded a net loss of $14.8 million ($0.47 per share) compared to net income of $15.6 million in Q3 2024.Key developments include:Multiple new development agreements signed with new and existing customersSale of unused filler equipment for $17 million, strengthening balance sheetAdjusted EBITDA of $5.7 million, down from $6.4 million year-over-yearGross profit decreased to $9.8 million from $11.9 millionThe company maintained its fiscal 2025 guidance, expecting revenue of $126.5-130 million and Adjusted EBITDA of $19-21 million.

#LFCR Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Lifecore Secures Major Defense Contract: Inside the $5.1M Radiation Protection Drug Program Lifecore expands CDMO portfolio with DoD-funded BIO 300 development, targeting radiation protection for military, cancer patients, and COVID-19 treatment. $5.1M contract value.

#LFCR Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome

www.stocktitan.net/news/LFCR/humanetics-sel...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Lifecore Biomedical Calls Special Meeting to Vote on Preferred Stock Conversion Cap Removal Stockholders to vote April 10 on removing 19.99% conversion limit for Series A Preferred Stock. Potential conversion could yield up to 6,056,284 common shares.

#LFCR Lifecore Biomedical Announces Special Stockholder Meeting

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

Just In: ( NASDAQ: #LFCR ) Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Lifecore Biomedical Secures $17M Equipment Sale, Doubles Production Capacity with New Filler Lifecore receives $7M upfront from isolator filler sale while new high-speed equipment installation boosts annual revenue potential to $300M, enhancing growth prospects.

#LFCR Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Lifecore Biomedical Revenue Grows 8% as Company Doubles Production Capacity and Signs New Deals Lifecore reports Q2 revenue of $32.6M, expands manufacturing with high-speed isolator filler, secures $24.3M funding, and adds new development projects while regaining Nasdaq compliance.

#LFCR Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Lifecore Biomedical Lands Key CDMO Partnership for Novel Addiction Treatment Drug Development Lifecore Biomedical secures strategic CDMO agreement with Nirsum Labs for NRS-033, an innovative opioid and alcohol addiction treatment entering Phase 2 trials.

#LFCR Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #LFCR ) Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation

#StockMarket #News

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#LFCR Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO

www.stocktitan.net/news/LFCR/lifecore-biome...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#LFCR Lifecore Biomedical Hosts Virtual Investor Day

www.stocktitan.net/news/LFCR/lifecore-biome...

1 0 0 0